Email updates

Keep up to date with the latest news and content from Critical Care and BioMed Central.

This article is part of the supplement: Sepsis 2012

Poster presentation

AMP-activated protein kinase preserves endothelial tight junctions in the coronary microcirculation during sepsis

D Castanares-Zapatero1*, C Bouleti2, T Mathivet2, B Gerber1, C Oury3, L Bertrand1, JL Vanoverschelde1, PF Laterre4, S Horman1 and C Beauloye1

  • * Corresponding author: D Castanares-Zapatero

Author Affiliations

1 Université catholique de Louvain, Institut de recherche expérimentale et clinique (pôle cardiovasculaire), Brussels, Belgium

2 Collège de France, Centre Interdisciplinaire de Recherche en Biologie INSERM 1050, Paris, France

3 Université de Liège, Groupe Interdisciplinaire de Génoprotéomique Appliquée, Liège, Belgium

4 Université catholique de Louvain, Cliniques universitaires Saint Luc Intensive Care Unit, Brussels, Belgium

For all author emails, please log on.

Critical Care 2012, 16(Suppl 3):P30  doi:10.1186/cc11717


The electronic version of this article is the complete one and can be found online at: http://ccforum.com/content/16/S3/P30


Published:14 November 2012

© 2012 Castanares-Zapatero et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background

A compromising endothelial cell (EC) monolayer affects vascular permeability and leads to fluid extravasation. Tight junctions and more particularly Zonula occludens 1 (ZO-1) play a major role in maintaining vascular barrier integrity and are regulated by cytoskeletal proteins. During sepsis, endothelial barrier disruption occurs in most organs and contributes to organ dysfunction. We and others have demonstrated that the α1 isoform of AMP-activated protein kinase (α1AMPK) controls cytoskeleton organisation in various cell types including endothelial cells. Therefore, we hypothesised that α1AMPK preserves tight junction organisation and vascular permeability during sepsis in the coronary microcirculation.

Methods

In vitro, tight junction organisation (ZO-1 staining), cytoskeleton organisation (phalloïdin staining) and vascular permeability were measured in endothelial cells in culture (HCAECs). Endothelial cells were pretreated with 1 mM AICA riboside (AICAr) before LPS challenge (50 μg/ml O55:B5). In vivo, wild-type (α1AMPK+/+) mice were treated with LPS (O55:B5,10 mg/kg) and compared with α1AMPK knockout animals (α1AMPK-/-). ZO-1 localisation was determined on frozen heart sections. Vascular permeability was evaluated using Evans Blue dye leakage. In addition, myocardial wall oedema was assessed by magnetic resonance imaging (MRI).

Results

In vitro, LPS-challenged cells displayed a significant disruption of the ZO-1 linear configuration after 24 hours and exhibited a decrease in peripheral actin filaments. Gap areas appeared in the cellular monolayer exposed to LPS, unlike untreated cells for which the monolayer remained unaltered. Consequently, LPS treatment gradually increased endothelial cells monolayer permeability in a time-dependent manner. AMPK activation by AICAr preserved the linear pattern of ZO-1 and prevented gap areas in the monolayer. More interestingly, AMPK activation reduced LPS-induced hyperpermeability. In vivo, according to the in vitro experiments, a dramatic decrease in ZO-1 staining was observed in α1AMPK-/- hearts compared with α1AMPK+/+, after LPS challenge. This resulted in an increased Evans Blue extravasation and, more importantly, in an exaggerated myocardial wall oedema observed by MRI. Finally, treating C57Bl6 mice with AICAr reduced cardiac vascular hyperpermeability in our model of sepsis.

Conclusion

The AMPK signalling pathway protects the endothelial barrier during sepsis by preserving tight junction organisation. Since AMPK counteracts the molecular events involved in the LPS-induced barrier disruption in coronary microcirculation, it could consequently represent a new therapeutic molecule during sepsis.